DOCTOR FUNGUS
CME program -
"Advances in the Prevention and Management of Invasive Fungal Infections"

Complete lectures from the satellite symposium preceding the 40th annual meeting of the Infectious Disease Society of America (IDSA), October 24, 2002 Chicago, Illinois		  
Disclosure of commercial interests

Paul O. Gubbins, PharmD
  • Fujisawa Healthcare, Inc1,2,3
  • Merck 3
  • Pfizer 1,3
  • SIDP 1
1=Grant/research support | 2=Consultant
3=Speaker's bureau | 4=Stock shareholder
5=Local investigator of clinical trials

Kieren A. Marr, M.D.
  • Biorad 1,2
  • Bristol-Myers Squibb 2
  • Fujisawa Healthcare, Inc. 2
  • Merck 1,2
  • Pfizer 1,2
  • Schering Plough 1,2


1=Grant/research support | 2=Consultant
3=Speaker's bureau | 4=Stock shareholder
5=Local investigator of clinical trials

Luis Ostrosky-Zeichner, M.D.
  • Elan 2
  • Fujisawa Healthcare, Inc. 1
  • Gilead 1
  • Merck 3
  • Ortho-Biotech 1
  • Pfizer 1
  • Schering Plough 2
1=Grant/research support | 2=Consultant
3=Speaker's bureau | 4=Stock shareholder
5=Local investigator of clinical trials

John H. Rex, M.D.
  • Bristol-Myers Squibb 1,2,3
  • Fujisawa Healthcare Inc. 1,2,3
  • Gilead 1,2,3
  • Janssen 1,2,3
  • Merck 1,2,3
  • Schering Plough 1,2,3
  • The Liposome Company 1,2,3
  • Versicor 1,2,3
1=Grant/research support | 2=Consultant
3=Speaker's bureau | 4=Stock shareholder
5=Local investigator of clinical trials

Jo-Anne van Burik, M.D.
  • Fujisawa Healthcare, Inc. 2,5
  • Merck 5
  • Pfizer 3
  • Roche 5
  • Schering Plough 2,5
upTop of page
  
Close this window